tiprankstipranks
Trending News
More News >
Syncom Formulation (India) Ltd. (IN:SYNCOMF)
:SYNCOMF
India Market
Advertisement

Syncom Formulation (India) Ltd. (SYNCOMF) Price & Analysis

Compare
1 Followers

SYNCOMF Stock Chart & Stats


SYNCOMF FAQ

What was Syncom Formulation (India) Ltd.’s price range in the past 12 months?
Syncom Formulation (India) Ltd. lowest stock price was ₹14.10 and its highest was ₹27.94 in the past 12 months.
    What is Syncom Formulation (India) Ltd.’s market cap?
    Syncom Formulation (India) Ltd.’s market cap is ₹16.93B.
      When is Syncom Formulation (India) Ltd.’s upcoming earnings report date?
      Syncom Formulation (India) Ltd.’s upcoming earnings report date is Aug 18, 2025 which is in 15 days.
        How were Syncom Formulation (India) Ltd.’s earnings last quarter?
        Currently, no data Available
        Is Syncom Formulation (India) Ltd. overvalued?
        According to Wall Street analysts Syncom Formulation (India) Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Syncom Formulation (India) Ltd. pay dividends?
          Syncom Formulation (India) Ltd. pays a Notavailable dividend of ₹0.03 which represents an annual dividend yield of N/A. See more information on Syncom Formulation (India) Ltd. dividends here
            What is Syncom Formulation (India) Ltd.’s EPS estimate?
            Syncom Formulation (India) Ltd.’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Syncom Formulation (India) Ltd. have?
            Syncom Formulation (India) Ltd. has 940,000,000 shares outstanding.
              What happened to Syncom Formulation (India) Ltd.’s price movement after its last earnings report?
              Currently, no data Available
              Which hedge fund is a major shareholder of Syncom Formulation (India) Ltd.?
              Currently, no hedge funds are holding shares in IN:SYNCOMF

              Company Description

              Syncom Formulation (India) Ltd.

              Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It offers various products, including generics, alpha adrenoceptor agonists, analgesics, antipyretics, anti-inflammatory, anti-ulcer agents, antibiotics, antidepressants, antifungals, antihistamines, antimalarial, antiplatelet agents, antiprotozoal, antivirals, bronchodilators, calcium antagonists, cardiac medicines, central nervous stimulants, cephelo sporins, cortico steroids, estrogen, cough suppressants, erectile dysfunction, and electrolite. The company also provides histamines, homeostatic, hypoglycemic, hypolipidaemics, local anesthetics, multivitamins and nutritional supplements, sedative anticonvulsants, stimulants, and sympathomimetic products, as well as products used in the treatment of gout. In addition, it engages in the trading of commodities and renting of properties. Further, the company exports its products. It offers its pharmaceutical formulations products in various dosage forms, such as tablets, capsules, liquids orals, liquid vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and herbals. Syncom Formulations (India) Limited was founded in 1985 and is based in Indore, India.

              Syncom Formulation (India) Ltd. (SYNCOMF) Earnings & Revenues

              Currently, no data available
              Please return soon. This page is being updated.
              Similar Stocks
              Company
              Price & Change
              Follow
              GRP Ltd
              Knowledge Marine & Engineering Works Limited
              Media Matrix Worldwide Limited
              Updater Services Limited
              Uniparts India Ltd.
              Popular Stocks
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis